Oxford/AstraZeneca COVID vaccine nasal spray fails in trial
The nasal version of the Oxford/AstraZeneca COVID vaccine failed to elicit an antibody response in an early trial and the company is shelving its development
The nasal version of the Oxford/AstraZeneca COVID vaccine failed to elicit an antibody response in an early trial and the company is shelving its development Read More
